According to the study, this dysregulation was correlated with the prognosis of osteosarcoma patients, with those exhibiting high levels of Bcl‐2 expression had a poorer prognosis and stronger tumor metastasis compared to patients with low levels of Bcl‐2 expression. This evidence concerns the gene BCL2 and osteosarcoma.